The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis

Inflammation Research

Volumn 65, Issue 7, 2016, Pages 511-520

  Safarzadeh, Elham ^a,b   Jadidi Niaragh, Farhad ^c   Motallebnezhad, Morteza ^b   Yousefi, Mehdi ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adenosine; Adenosine receptor; Experimental autoimmune encephalomyelitis; Multiple sclerosis

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; CVT 6883; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; UNCLASSIFIED DRUG;

B LYMPHOCYTE; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INFLAMMATION; ISCHEMIA; MACROPHAGE; METABOLIC STRESS; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE; TISSUE INJURY; ANIMAL; IMMUNOLOGY;

ADENOSINE; ANIMALS; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, PURINERGIC P1;

EID: 84960124239     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-016-0936-z     Document Type: Review

References (90)

1. Selter RC, Hemmer B. Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther. 2013;2:21–30.
2. Gharibi T, et al. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis. Cell Immunol. 2015;293(2):113–21.
3. Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis a systematic review. Neurology. 2008;71(2):129–35.
4. Damal K, Stoker E, Foley JF. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biol Targets Ther. 2013;7:247.
5. Mirshafiey A, Jadidi-Niaragh F. Prostaglandins in pathogenesis and treatment of multiple sclerosis. Immunopharmacol Immunotoxicol. 2010;32(4):543–54.
6. Mulakayala N, et al. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview. Eur J Med Chem. 2013;60:170–86.
7. Jadidi-Niaragh F, Mirshafiey A. Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. Neuropharmacology. 2010;59(3):180–9.
8. Masino S, Boison D. Adenosine: a key link between metabolism and brain activity. New York: Springer; 2012.
9. Sperlágh B, Illes P. Purinergic modulation of microglial cell activation. Purinergic Signal. 2007;3(1–2):117–27.
10. Mayne M, et al. Dysregulation of adenosine A1 receptor–mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol. 1999;45(5):633–9.
11. Nakahara J, et al. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol. 2012;42(1):26–34.
12. Ciccarelli O, et al. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 2014;13(8):807–22.
13. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011;74(1):1–13.
14. Mirshafiey A, et al. The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis. Sultan Qaboos Univ Med J. 2014;14(1):e13.
15. Mirshafiey A, Jadidi-Niaragh F. Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis. Immunopharmacol Immunotoxicol. 2010;32(2):219–27.
16. Jadidi-Niaragh F, Mirshafiey A. Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis. Immunopharmacol Immunotoxicol. 2011;33(3):545–67.
17. Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci. 2013;333(1):1–4.
18. D’Aversa TG, et al. Myelin basic protein induces inflammatory mediators from primary human endothelial cells and blood–brain barrier disruption: implications for the pathogenesis of multiple sclerosis. Neuropathol Appl Neurobiol. 2013;39(3):270–83.
19. Fischer M, et al. Research highlights inflammation, demyelination and neurodegeneration: risky buddies in multiple sclerosis. CNS Neurol Disord Drug Targets. 2014;13(1):1.
20. Hussain RZ, et al. Immune surveillance of the central nervous system in multiple sclerosis—Relevance for therapy and experimental models. J Neuroimmunol. 2014;276(1):9–17.
21. Neuhaus O, Archelos JJ, Hartung H-P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci. 2003;24(3):131–8.
22. Aktas O, Kieseier B, Hartung H-P. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 2010;33(3):140–52.
23. Jadidi-Niaragh F, Mirshafiey A. Therapeutic approach to multiple sclerosis by novel oral drugs. Recent Pat Inflamm Allergy Drug Discov. 2011;5(1):66–80.
24. Vincenzi F, et al. Multiple sclerosis lymphocytes upregulate A2A adenosine receptors that are antiinflammatory when stimulated. Eur J Immunol. 2013;43(8):2206–16.
25. Sachdeva S, Gupta M. Adenosine and its receptors as therapeutic targets: an overview. Saudi Pharm J. 2013;21(3):245–53.
26. Cacciari B, et al. A2B adenosine receptor antagonists: recent developments. Mini Rev Med Chem. 2005;5(12):1053–60.
27. Newby AC. Adenosine and the concept of ‘retaliatory metabolites’. Trends Biochem Sci. 1984;9(2):42–4.
28. Desrosiers MD, et al. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol. 2007;179(3):1884–92.
29. Gessi S, et al. A2A adenosine receptors in human peripheral blood cells. Br J Pharmacol. 2000;129(1):2–11.
30. Cristalli G, et al. Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev. 2001;21(2):105–28.
31. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25(1):33–9.
32. King AE, et al. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci. 2006;27(8):416–25.
33. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res. 2010;316(8):1284–8.
34. Deussen A. Metabolic flux rates of adenosine in the heart. Naunyn Schmiedeberg’s Arch Pharmacol. 2000;362(4–5):351–63.
35. Thompson LF, et al. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med. 2004;200(11):1395–405.
36. Eltzschig HK, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood. 2004;104(13):3986–92.
37. Milne GR, Palmer TM. Anti-inflammatory and immunosuppressive effects of the A 2A adenosine receptor. Sci World J. 2011;11:320–39.
38. Bours M, et al. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006;112(2):358–404.
39. Moriwaki Y, Yamamoto T, Higashino K. Enzymes involved in purine metabolism-a review of histochemical localization and functional implications. Histol Histopathol. 1999;14(4):1321–40.
40. Matsumoto T, Tostes RC, Webb RC. Alterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive rats. Pharmacol Res. 2012;65(1):81–90.
41. Haskó G, et al. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther. 2007;113(2):264–75.
42. Fredholm BB, et al. Structure and function of adenosine receptors and their genes. Naunyn Schmiedeberg’s Arch Pharmacol. 2000;362(4–5):364–74.
43. −adenosine receptors coupled to adenylate cyclase. Biochem Pharmacol. 1992;43(5):1089–93.
44. Livingston M, Heaney L, Ennis M. Adenosine, inflammation and asthma–a review. Inflamm Res. 2004;53(5):171–8.
45. Chen J-F, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets—what are the challenges? Nat Rev Drug Discov. 2013;12(4):265–86.
46. Fredholm BB, et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev. 2011;63(1):1–34.
47. Carlsson J, et al. Structure-based discovery of A2A adenosine receptor ligands. J Med Chem. 2010;53(9):3748–55.
48. Sitkovsky MV. Use of the A 2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol. 2003;65(4):493–501.
49. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol. 1994;76(1):5–13.
50. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414(6866):916–20.
51. Gessi S, et al. Adenosine and lymphocyte regulation. Purinergic Signal. 2007;3(1–2):109–16.
52. 2B Adenosine Receptors Promote Carcinoma Growth. Neoplasia. 2008;10(9):987–95.
53. Zhong H, et al. Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol. 2003;171(1):338–45.
54. Haskó G, et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759–70.
55. Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochi Biophys Acta (BBA) Biomembr. 2011;1808(5):1290–308.
56. Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):247–64.
57. Mills J, et al. Never underestimate the power of adenosine in multiple sclerosis. CNS Neurol Disorders Drug Targets. 2013;12(7):1.
58. Johnston JB, et al. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol. 2001;49(5):650–8.
59. Koedel U, et al. Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis. PLoS Pathog. 2009;5(5):e1000461.
60. Naegele M, et al. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol. 2012;242(1):60–71.
61. Mossberg N, et al. Oxygen radical production in leukocytes and disease severity in multiple sclerosis. J Neuroimmunol. 2009;213(1):131–4.
62. Hernández-Pedro NY et al. Initial immunopathogenesis of multiple sclerosis: innate immune response. Clin Dev Immunol. 2013;2013:413465.
63. Csóka B, et al. A2A adenosine receptors and C/EBPβ are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood. 2007;110(7):2685–95.
64. Tsutsui S, et al. Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and β-arrestin-1 in monocytoid cells. FASEB J. 2008;22(3):786–96.
65. 2) receptor selective agonists. Int J Immunopharmacol. 1995;17(3):221–4.
66. La Sala A, Gadina M, Kelsall BL. Gi-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J Immunol. 2005;175(5):2994–9.
67. Koscsó B, et al. Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process. J Immunol. 2012;188(1):445–53.
68. Saijo K, Crotti A, Glass CK. Regulation of microglia activation and deactivation by nuclear receptors. Glia. 2013;61(1):104–11.
69. Bi W, et al. Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation. Brain Res. 2011;1395:12–20.
70. Koning N, et al. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol. 2007;62(5):504–14.
71. Sevigny CP, et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol. 2007;178(7):4240–9.
72. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-γ production in murine CD4 + T cells. J Immunol. 2005;174(2):1073–80.
73. Johnston A, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005;114(2):154–63.
74. 7 integrin-mediated adhesion of T lymphocytes to colon adenocarcinoma cells. Exp Cell Res. 2002;276(1):90–100.
75. Yang Z, et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation. 2005;111(17):2190–7.
76. Wei W, et al. Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. J Immunol. 2013;190(1):138–46.
77. Buc M. Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis. Mediators Inflamm. 2013;2013:11. doi:10.1155/2013/963748.
78. Lowther DE, Hafler DA. Regulatory T cells in the central nervous system. Immunol Rev. 2012;248(1):156–69.
79. Buckner JH. Mechanisms of impaired regulation by CD4 + CD25 + FOXP3 + regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10(12):849–59.
80. Yao SQ, et al. Genetic inactivation of the adenosine A2A receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis. J Neurochem. 2012;123(1):100–12.
81. Mills JH, et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci. 2008;105(27):9325–30.
82. Dai S-S, Zhou Y-G. Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury. Rev Neurosci. 2011;22(2):231–9.
83. Engelhardt B. T cell migration into the central nervous system during health and disease: different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol. 2010;1(2):79–93.
84. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol. 2009;193:535–587.
85. Chen J-F, et al. Adenosine A 2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. Prog Neurobiol. 2007;83(5):310–31.
86. Tsutsui S, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci. 2004;24(6):1521–9.
87. Chen GQ, et al. Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. Brain Res. 2010;1309:116–25.
88. Mills JH, et al. A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. J Immunol. 2012;188(11):5713–22.
89. Melani A, et al. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain. 2009;132(6):1480–95.
90. Loram LC, et al. Adenosine 2A receptor agonism: a single intrathecal administration attenuates motor paralysis in experimental autoimmune encephalopathy in rats. Brain Behav Immun. 2015;46:50–4.